HIVE vs GEMI

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 12, 2026

HIVE

48.3
AI Score
VS
HIVE Wins

GEMI

42.7
AI Score

Investment Advisor Scores

HIVE

48score
Recommendation
HOLD

GEMI

43score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric HIVE GEMI Winner
Revenue 79.12M 95.75M GEMI
Net Income -142.91M -216.70M HIVE
Net Margin -180.6% -226.3% HIVE
ROE -33.8% -46.3% HIVE
ROA -15.5% -14.4% GEMI
Total Assets 924.64M 1.50B GEMI
Cash 208.04M 188.62M HIVE
Current Ratio 1.96 1.30 HIVE

Relative Price Performance (Last 90 Days)

HIVE 1M: +10.6% · 3M: -20.1% GEMI 1M: +7.0% · 3M: -3.9%

Current Technical Phase

HIVE

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 52

RSI (14): 51.8 · Price: $3.03

GEMI

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 52

RSI (14): 51.9 · Price: $4.46

Fundamentals Snapshot

Metric HIVE GEMI
Market Cap
Forward P/E -5.9 -2.2
Trailing P/E
Revenue (TTM)
Revenue Growth 0.7% 0.4%
Gross Margin 0.4% -0.3%
Operating Margin -0.6% -1.7%
EPS -1.33 -14.81
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.